Ironwood inks $345M partnership on anti-anxiety drug program

Cambridge, MA-based Ironwood Pharmaceuticals ($IRWD) is partnering with Australia's Bionomics to develop an experimental anti-anxiety drug. Bionomics gets a $16 million near-term deal--$3 million upfront and the rest over 24 months--in the pact. And the biotech stands to gain up to $345 million plus royalties from Ironwood for a successful program.

The focus of the deal is on BNC210, which has ginned some positive Phase I data on anti-anxiety activity without the sedative side effects often linked to benzodiazepines, a class of drugs now used to treat anxiety. The deal marks a new stage for Ironwood, which has been closely focused on the development of linaclotide, a potential IBS blockbuster now up for review by the FDA. The decision on that program is due by June.

"Partnering BNC210 has been a major objective for Bionomics, and this collaboration with Ironwood continues Bionomics' strategy to form partnerships to develop and commercialize its proprietary drug candidates," said Deborah Rathjen, Bionomics CEO.

- here's the press release

Suggested Articles

The inclusion of Kupffer cells in in vitro hepatic cultures provides researchers with advanced tools for disease modeling and drug discovery.

A delay to Moderna's phase 3 COVID-19 study is part of a trend of tensions in the biotech’s relationship with the U.S. government, Reuters reported.

GlaxoSmithKline is continuing its strategy of giving out access to its vaccine platform as it adds Medicago to its growing partners list.